Volume 37, No. 10, page 5886 (only in the printed version): Results lines 1 to 26 should read:
Patients' characteristics. The clinical characteristics of the 199 patients are summarized in Table I. The median age was 68 years old, 67% of the patients were men, and most (78%) had a smoking history. The ECOG PS of 92% of the patients was ≤2. The most common histology was adenocarcinoma (70%); 18% of patients had EGFR mutations and only one had an ALK mutation. Seventy-seven patients (39%) were administrated nivolumab as second-line therapy, 44 (22%) as third-line, and 78 (39%) as fourth or subsequent lines.
ORR and DCR following nivolumab treatment based on the pretreatment response. Among the patients who achieved CR or PR following pre-nivolumab chemotherapy, ORR and DCR rates after nivolumab were 16% and 64%, respectively. In contrast, patients who did not achieve CR or PR (including those with stable disease [SD], progressive disease [PD], or were not evaluable [NE]) following previous treatments experienced a post-nivolumab ORR and DCR of 15% and 46%, respectively (Table II). There was no significant difference in terms of good response to nivolumab between patients who achieved good response to pretreatment chemotherapy and those who did not (p=1.00); however, the DCR following nivolumab was significantly higher in patients who achieved clinical response in previous treatments (p=0.03). Among patients who achieved disease control with pre-nivolumab chemotherapy, the ORR and DCR following nivolumab were 16% and 61%, respectively
- Copyright© 2017, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved